Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Reports $5.4 Million Loss in Q3

NEW YORK (GenomeWeb) – Trovagene announced Thursday after the close of the market that its third quarter net loss widened as its revenues inched up to $57,000 from $44,000 in Q3 2014.

The firm posted a net loss of $5.4 million, or $.28 per share, for the three months ended Sept. 30, as compared to a net loss of $4.4 million, or $.25 per share, in Q3 2014.

The increased loss is primarily due to an increase in operating expenses as compared to a year ago, the firm said in a statement.

Its R&D spending rose 117 percent to $2.0 million, up from $916,000, and its SG&A spending fell 9 percent to $2 million from $2.2 million.

San Diego-based Trovagene is developing a cell-free molecular diagnostic platform for the detection and monitoring of DNA in urine, offering physicians a non-invasive method to determine mutations and monitor response to cancer.

Trovagene CEO Antonius Schuh said that the firm's cell-free cancer diagnostic assay is gaining recognition within the medical community. "Recently published data in the journal Cancer Discovery demonstrates that urinary cell-free DNA can outperform tissue biopsy for the detection of the BRAF V600E mutation," Schuh said.

The firm also recently expanded its relationship with Memorial Sloan-Kettering to include a new clinical study evaluating its precision cancer monitoring platform in lung cancer.

Trovagene finished the quarter with cash and cash equivalents of $31.2 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.